Efficacy of recombinant tissue plasminogen activator combined with edaravone and dexborneol for arterial thrombolysis
10.3969/j.issn.1009-0126.2024.08.013
- VernacularTitle:重组组织型纤溶酶原激活剂动脉溶栓联合依达拉奉右莰醇的临床疗效分析
- Author:
Liejun WEI
1
;
Lili ZHAO
;
Xiao LI
Author Information
1. 733000 武威市凉州医院神经内科
- Keywords:
brain infarction;
thrombolytic therapy;
plasminogen activators;
edaravone
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2024;26(8):916-920
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical therapeutic efficacy of edaravone and dexborneol in elderly patients with posterior circulation perforating arterial cerebral infarction after receiving rt-PA for arterial thrombolysis.Methods A total of 68 elderly patients with acute cerebral infarction who were treated in our hospital from August 2021 to August 2023 were enrolled and then ran-domly divided into thrombolytic group and combined group,with 34 cases in each group.The thrombolytic group was treated with rt-PA arterial thrombolysis,and the combined group was treated with edaravone and dexborneol on the basis of thrombolytic group.The therapeutic effica-cy,neurological function,oxidative stress reaction,inflammatory reaction,ADL,and incidence of adverse events were compared between the two groups.Results There was no significant differ-ence in the total effective rate between the two groups(P＞0.05).Serum levels of NSE,MMP-9,S100β,MDA,IL-6 and CRP,and the scores of mRS and NIHSS were all decreased in the two groups in 14 d after treatment than before treatment(P＜0.05),and the levels of NSE,MMP-9,S100β,MDA,IL-6 and CRP,and mRS score and NIHSS score were obviously lower in the com-bined group than the thrombolytic group at the time point(P＜0.05,P＜0.01).After 90 days'treatment,the combined group obtained notably lower NIHSS score than the thrombolytic group(6.15±0.92 vs 7.48±0.83,P＜0.01).After 14 days of treatment,the level of SOD and Barthel in-dex in the two groups were higher than those before treatment(P＜0.05),and the two indicators in the combined group were higher than those in the thrombolytic group(P＜0.01).No statistical difference was observed in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Concurrent administration of edaravone and dexborneol shows good clinical ef-ficacy for elderly patients with cerebral infarction with perforating artery of posterior circulation after rt-PA arterial thrombolytic therapy,and at the same time,the combination of edaravone and dextromethorphan had a better clinical effect,which can reduce oxidative stress and inflammatory reaction,improve brain tissue damage and neurological function,and promote the ability of daily living,with better safety.
